Steven K. Galson Purchases 21,940 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steven K. Galson bought 21,940 shares of the company's stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $5.49 per share, for a total transaction of $120,450.60. Following the transaction, the director now directly owns 51,551 shares of the company's stock, valued at approximately $283,014.99. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

BioCryst Pharmaceuticals Trading Up 18.7 %

NASDAQ BCRX traded up $1.00 on Wednesday, hitting $6.36. 10,480,656 shares of the company were exchanged, compared to its average volume of 3,467,914. The firm has a 50 day moving average of $4.88 and a two-hundred day moving average of $5.45. The company has a market cap of $1.31 billion, a P/E ratio of -5.77 and a beta of 1.96. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. The business's revenue for the quarter was up 34.9% on a year-over-year basis. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BCRX. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "market outperform" rating in a report on Tuesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 2,388 shares during the period. Teacher Retirement System of Texas increased its stake in shares of BioCryst Pharmaceuticals by 4.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company's stock valued at $380,000 after acquiring an additional 2,519 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 3,500 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 4,041 shares during the last quarter. Finally, Teza Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 12.8% in the 3rd quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company's stock valued at $261,000 after acquiring an additional 4,180 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.